Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Recommendation of “Buy” by Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have received a consensus rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.80.

A number of research analysts recently weighed in on ACHV shares. Raymond James started coverage on Achieve Life Sciences in a report on Friday, September 27th. They set a “strong-buy” rating and a $20.00 price objective on the stock. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a report on Thursday. Oppenheimer reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Achieve Life Sciences in a report on Thursday, August 15th. Finally, Rodman & Renshaw started coverage on Achieve Life Sciences in a report on Thursday. They set a “buy” rating and a $12.00 price objective on the stock.

Achieve Life Sciences Price Performance

Achieve Life Sciences stock opened at $4.39 on Friday. Achieve Life Sciences has a 12 month low of $3.03 and a 12 month high of $5.98. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The business has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $4.76. The stock has a market capitalization of $150.97 million, a PE ratio of -3.88 and a beta of 1.57.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same period last year, the firm posted ($0.34) earnings per share. Equities analysts predict that Achieve Life Sciences will post -1.17 earnings per share for the current year.

Institutional Trading of Achieve Life Sciences

Several large investors have recently bought and sold shares of the company. MetLife Investment Management LLC grew its holdings in Achieve Life Sciences by 65.6% in the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Achieve Life Sciences during the third quarter valued at $54,000. Virtu Financial LLC acquired a new stake in shares of Achieve Life Sciences during the first quarter valued at $59,000. Renaissance Technologies LLC boosted its stake in shares of Achieve Life Sciences by 134.2% during the second quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 14,360 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Achieve Life Sciences during the second quarter valued at $69,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.